Polypharmacy in Osteoporosis Patients

Basit Öğe Kaydı
dc.contributor.authorKarahan, Yavuz Ali
dc.contributor.authorBasaran, Aynur
dc.contributor.authorOrdahan, Banu
dc.contributor.authorYildirim, Pelin
dc.contributor.authorKucuksarac, Seher
dc.contributor.authorOktar, Suleyman
dc.contributor.authorSoran, Neslihan
dc.date.accessioned2024-02-23T14:38:21Z
dc.date.available2024-02-23T14:38:21Z
dc.date.issued2015
dc.departmentNEÜen_US
dc.description.abstractObjective: In this study, it was aimed to determine the rates of multiple drug use in the patients with osteoporosis as well as the use of drugs affecting bone metabolism and balance. Materials and Methods: We included outpatients from Physical Medicine and Rehabilitation Policlinics diagnosed with primary or secondary osteoporosis between January 2014 and May 2014. Written consent of the participants was obtained. Data of the first 1000 patients who agreed to participate in the study were evaluated. Data regarding age, history, drugs currently being used and newly initiated were recorded. The drugs that affect bone metabolism were determined. The drugs that heva side effects including dizziness, somnolence, distractibility, decrease in the visual acuity, orthostatic hypotension and ototoxicity and were recorded because these can cause a balance disorder. Results: In this study, 64% of the participants were on five or more drugs. The most commonly used drugs were analgesics (65.4%), anti-hypertensives (52.6%), and drugs for digestive system (37.3%). We found that 65.5% of the participants were using drugs that may have side effects on bone metabolism and 93.7% were using drugs that may have side effects on balance. Conclusion: Multi-drug use and drug interactions should be considered during the treatment of osteoporosis and the drugs used should be recorded. Drugs that affect bone metabolism should only be used over the short term. Also, patients should be informed about side effects that might affect visuality, somatosensorial system and vestibular system and their daily activities should be regulated.en_US
dc.identifier.doi10.4274/tod.96720
dc.identifier.endpage9en_US
dc.identifier.issn2146-3816
dc.identifier.issn2147-2653
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-84926507181en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage5en_US
dc.identifier.urihttps://doi.org/10.4274/tod.96720
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16482
dc.identifier.volume21en_US
dc.identifier.wosWOS:000409953900003en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurk Osteoporoz Dergisi-Turkish Journal Of Osteoporosisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectOsteoporosisen_US
dc.subjectPolypharmacyen_US
dc.subjectDrugen_US
dc.subjectTreatmenten_US
dc.titlePolypharmacy in Osteoporosis Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu